July 2, 2014
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced the closing of its previously announced underwritten public offering of shares of its common stock, including all 697,500 shares subject to the underwriters' over-allotment option. After giving effect to the exercise of the over-allotment option, the Company sold an aggregate of 5,347,500 shares of common stock in the offering at a public offering price of
per share. The net proceeds of the offering are expected to be approximately
, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
Roth Capital Partners and Oppenheimer & Co. acted as joint book-running managers for the offering. Craig-Hallum Capital Group, LLC is acting as a financial advisor to the Company.
The Company intends to use the net proceeds of the offering for general corporate purposes, including, without limitation, research and development, general and administrative, manufacturing and marketing expenses, and potential not yet identified acquisitions of companies, products, ANDAs, technologies and assets that complement the Company's business.
This shares described above were offered pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying prospectus describing the terms of the offering have been filed with the SEC and are available on the SEC's website at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.